Pfizer Inc. (PFE)

NYSE: PFE · Real-Time Price · USD
24.50
-0.27 (-1.09%)
At close: Oct 28, 2025, 4:00 PM EDT
24.52
+0.02 (0.08%)
Pre-market: Oct 29, 2025, 4:24 AM EDT
-1.09%
Market Cap139.30B
Revenue (ttm)63.83B
Net Income (ttm)10.75B
Shares Out 5.69B
EPS (ttm)1.89
PE Ratio12.94
Forward PE8.56
Dividend$1.72 (7.02%)
Ex-Dividend DateNov 7, 2025
Volume50,144,923
Open24.78
Previous Close24.77
Day's Range24.38 - 24.78
52-Week Range20.92 - 29.17
Beta0.47
AnalystsHold
Price Target29.20 (+19.18%)
Earnings DateNov 4, 2025

About PFE

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]

Sector Healthcare
Founded 1849
Employees 81,000
Stock Exchange NYSE
Ticker Symbol PFE
Full Company Profile

Financial Performance

In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.

Financial Statements

Analyst Summary

According to 11 analysts, the average rating for PFE stock is "Hold." The 12-month stock price target is $29.2, which is an increase of 19.18% from the latest price.

Price Target
$29.2
(19.18% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Why Pfizer's Headwinds May Already Be In The Price

Pfizer faces significant revenue headwinds from patent expiries, COVID product declines, and generic competition, but these risks are largely priced in. PFE's valuation is historically low at ~8x earn...

4 days ago - Seeking Alpha

Buy 9 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 October Dividend Dogs

Nine of fifteen Barron's Better Bets (BBB) 'safer' high-yield dividend stocks are currently attractively priced, including CAG, VZ, MO, BMY, TFC, UDR, KEY, KIM, and RF. Analyst forecasts project top-t...

Other symbols: BBBBMYCAGEQRKEYKIMLYB
4 days ago - Seeking Alpha

Metsera Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Metse...

Other symbols: MTSR
5 days ago - Business Wire

These low-risk stocks could be a profitable answer to this volatile earnings season

Slow and steady performers do better over the long term.

Other symbols: AMGNBMYCVSGDGISHQYHRL
5 days ago - Market Watch

My Top 3 Pharma Stocks

Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and o...

8 days ago - Seeking Alpha

Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy

– Data demonstrated that vepdegestrant maintained patients' quality of life for statistically significantly longer and delayed worsening of overall health, daily functioning, and symptoms, including p...

Other symbols: ARVN
9 days ago - GlobeNewsWire

XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer

NEW YORK & NORTHBROOK, Ill.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) result...

10 days ago - Business Wire

Pfizer's BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for th...

10 days ago - Business Wire

Astellas-Pfizer's combination therapy halves risk of death in bladder cancer patients

Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor recurrence, progression or death in patients suffering from a type of bladder cancer, the comp...

10 days ago - Reuters

PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer

First and only combination regimen to improve survival when used before and after surgical cystectomy in cisplatin-ineligible patients with muscle-invasive bladder cancer Unprecedented survival result...

10 days ago - PRNewsWire

Pfizer: World-Leading Drug Pipeline Sets Stage For Major Long-Term Potential

Pfizer is rated a buy due to its robust drug pipeline, focus on improving financials, and significant long-term growth potential despite near-term headwinds. PFE delivered strong results in H1, with 1...

10 days ago - Seeking Alpha

Popular birth control is linked to brain tumors in new study — as over 1,000 women sue Pfizer over health risks

One Louisiana woman, Robin Phillip, said she developed an intracranial meningioma that caused her to lose vision in her left eye and struggle to walk.

11 days ago - New York Post

Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?

President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to...

Other symbols: LLY
11 days ago - Benzinga

What's Behind The Slump In Pfizer Stock?

Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of −11% of its value over that period. This sustained sell-off has wiped o...

11 days ago - Forbes

Pfizer: Don't Forget About Value During AI Frenzy

Pfizer is rated a Strong Buy, offering a nearly 7% forward dividend yield, which is highly likely safe. PFE's revenue has stabilized, management is delivering cost savings, and a recent drug pricing d...

12 days ago - Seeking Alpha

CEOs of Wells Fargo and Pfizer caution the U.S. could lose its edge to China without innovation

Wells Fargo CEO Charlie Scharf said AI is boosting productivity but will likely reduce workforce size. Pfizer CEO Albert Bourla warned China is closing the biotech and pharmaceutical patent gap rapidl...

Other symbols: WFC
13 days ago - CNBC

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Other symbols: BMYPRGO
13 days ago - Benzinga

Pfizer CEO says US pharma industry needs to collaborate with China

Pfizer Chief Executive Albert Bourla said on Tuesday that the U.S. pharmaceutical industry needs to collaborate with China's, where speedy processes have vaulted it to 30% of global drug development o...

14 days ago - Reuters

TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUK...

14 days ago - Business Wire

Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) will present data across its infectious disease portfolio at the upcoming IDWeek 2025 congress, held in Atlanta from October 19-22, 2025. D...

15 days ago - Business Wire

Buy Any Of 14 IDEAL 'Safer' S&P 500 October Dividend Dogs

Fourteen of the highest-yielding, 'safer' S&P 500 dividend stocks are currently attractively priced, with free cash flow supporting their payouts. Top ten S&P 500 dividend 'dogs' are projected to deli...

Other symbols: AESAMCRAREBMYCAGCPBDOC
16 days ago - Seeking Alpha

Biotech Stocks Have Struggled Since 2021. Why They're Coming Back.

Too many questionable start-ups went public during the pandemic, when the sector was hot. Now, after over four years of pain, the weak have failed, rates are falling, and M&A looks to be on the upswin...

Other symbols: MRKXBI
18 days ago - Barrons

Pfizer's Q3: The Catalyst For A Bullish Resurgence (Earnings Preview)

Pfizer's stock is poised for recovery, driven by recent corporate news and a three-year reprieve on drug-import tariffs from the Trump administration, strengthening the bullish case despite prior mark...

18 days ago - Seeking Alpha

Pfizer Declares Fourth-Quarter 2025 Dividend

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2025 dividend on the company's common stock, payable December 1, 2025, to...

19 days ago - Business Wire

Mikael Dolsten, M.D., Ph.D., Joins TRIO Pharmaceuticals as Chairman

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $PFE #ADCs--Mikael Dolsten, M.D., Ph.D., Joins TRIO Pharmaceuticals as Chairman.

20 days ago - Business Wire